Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.

Current gastroenterology reports - 1 Feb 2012

Gambarin-Gelwan Maya, Jacobson Ira M

Abstract excerpt

Direct-acting antiviral agents in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) significantly improve sustained virologic response rate and reduce duration of therapy among both treatment-naïve and treatment-experienced patients with genotype 1 chronic hepatitis C. One of the most important considerations with both boceprevir and telaprevir is the potential development of resistant variants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Genetic Variation
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Source

Identifiers

PMID: 22161022
DOI: 10.1007/s11894-011-0237-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.PMID 22161022Read ↗

The role of resistance in HCV treatment.Semantic proximity Read ↗

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Semantic proximity Read ↗

Resistance to hepatitis C virus protease inhibitors.Semantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.Semantic proximity Read ↗

Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.Semantic proximity Read ↗

Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.Semantic proximity Read ↗

Hepatitis C virus resistance to the new direct-acting antiviralsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.